title: The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
abstract: OBJECTIVE
  The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. The authors report effectiveness outcomes across a 1-year naturalistic follow-up period.
  
  
  METHODS
  The randomized, controlled trial was conducted in 13 academic and community sites in the United States. Stages I, II, and III consisted of 12, 6, and 18 weeks of acute, consolidation, and continuation treatment, respectively. Following discontinuation of TADS treatments at the end of stage III, stage IV consisted of 1 year of naturalistic follow-up. The participants were 327 subjects between the ages of 12 and 17 with a primary DSM-IV diagnosis of major depressive disorder. No TADS treatment was provided during the follow-up period; treatment was available in the community. The primary dependent measures, rated by an independent evaluator blind to treatment status, were the total score on the Children's Depression Rating Scale-Revised and the rate of response, defined as a rating of much or very much improved on the Clinical Global Impressions improvement measure.
  
  
  RESULTS
  Sixty-six percent of the eligible subjects participated in at least one stage IV assessment. The benefits seen at the end of active treatment (week 36) persisted during follow-up on all measures of depression and suicidality.
  
  
  CONCLUSIONS
  In contrast to earlier reports on short-term treatments, in which worsening after treatment is the rule, the longer treatment in the TADS was associated with persistent benefits over 1 year of naturalistic follow-up.
authors.affiliation: Department of Psychiatry and Behavioral Sciences and the Duke Clinical Research Institute at Duke University Medical Center, Durham, NC 27705, USA. john.march@duke.edu
authors.forename: John
authors.initials: J
authors.lastname: March
authors.forename: Susan
authors.initials: S
authors.lastname: Silva
authors.forename: John
authors.initials: J
authors.lastname: Curry
authors.forename: Karen
authors.initials: K
authors.lastname: Wells
authors.forename: John
authors.initials: J
authors.lastname: Fairbank
authors.forename: Barbara
authors.initials: B
authors.lastname: Burns
authors.forename: Marisa
authors.initials: M
authors.lastname: Domino
authors.forename: Benedetto
authors.initials: B
authors.lastname: Vitiello
authors.forename: Joanne
authors.initials: J
authors.lastname: Severe
authors.forename: Karyn
authors.initials: K
authors.lastname: Riedal
authors.forename: Marguerita
authors.initials: M
authors.lastname: Goldman
authors.forename: Norah
authors.initials: N
authors.lastname: Feeny
authors.forename: Robert
authors.initials: R
authors.lastname: Findling
authors.forename: Sheridan
authors.initials: S
authors.lastname: Stull
authors.forename: Susan
authors.initials: S
authors.lastname: Baab
authors.forename: Elizabeth B
authors.initials: EB
authors.lastname: Weller
authors.forename: Michele
authors.initials: M
authors.lastname: Robbins
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Weller
authors.forename: Naushad
authors.initials: N
authors.lastname: Jessani
authors.forename: Bruce
authors.initials: B
authors.lastname: Waslick
authors.forename: Michael
authors.initials: M
authors.lastname: Sweeney
authors.forename: Randi
authors.initials: R
authors.lastname: Dublin
authors.forename: John
authors.initials: J
authors.lastname: Walkup
authors.forename: Golda
authors.initials: G
authors.lastname: Ginsburg
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Kastelic
authors.forename: Hyung
authors.initials: H
authors.lastname: Koo
authors.forename: Christopher
authors.initials: C
authors.lastname: Kratochvil
authors.forename: Diane
authors.initials: D
authors.lastname: May
authors.forename: Randy
authors.initials: R
authors.lastname: LaGrone
authors.forename: Brigette
authors.initials: B
authors.lastname: Vaughan
authors.forename: Anne Marie
authors.initials: AM
authors.lastname: Albano
authors.forename: Glenn S
authors.initials: GS
authors.lastname: Hirsch
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Podniesinki
authors.forename: Angela
authors.initials: A
authors.lastname: Chu
authors.forename: Mark
authors.initials: M
authors.lastname: Reincecke
authors.forename: Bennett
authors.initials: B
authors.lastname: Leventhal
authors.forename: Gregory
authors.initials: G
authors.lastname: Rogers
authors.forename: Rachel
authors.initials: R
authors.lastname: Jacobs
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Pathak
authors.forename: Jennifer
authors.initials: J
authors.lastname: Wells
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Lavanier
authors.forename: Arman
authors.initials: A
authors.lastname: Danielyan
authors.forename: Paul
authors.initials: P
authors.lastname: Rohde
authors.forename: Anne
authors.initials: A
authors.lastname: Simons
authors.forename: James
authors.initials: J
authors.lastname: Grimm
authors.forename: Stephanie
authors.initials: S
authors.lastname: Frank
authors.forename: Graham
authors.initials: G
authors.lastname: Emslie
authors.forename: Beth
authors.initials: B
authors.lastname: Kennard
authors.forename: Carroll
authors.initials: C
authors.lastname: Hughes
authors.forename: Taryn L
authors.initials: TL
authors.lastname: Mayes
authors.forename: David
authors.initials: D
authors.lastname: Rosenberg
authors.forename: Nili
authors.initials: N
authors.lastname: Benazon
authors.forename: Michael
authors.initials: M
authors.lastname: Butkus
authors.forename: Marla
authors.initials: M
authors.lastname: Bartoi
mesh_terms: D000293:Adolescent; D002648:Child; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors